Effect for sodium sensitivity of blood pressure of empagliflozin, sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus

Effect for sodium sensitivity of blood pressure of empagliflozin, sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus - Effect for sodium sensitivity of blood pressure of empagliflozin, sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026537

Enrollment

100

Registered

2017-03-29

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

A period of intervention is 16 days.First 4 days, patient have a meal, contain a salt 10 g/day.Next 4days, they have a diet, contain a salt 6g/day.From the following day, they spend same 8days ,taking

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: eGFR of patient is more than 45ml/min/1.73m2.

Exclusion criteria

Exclusion criteria: advanced liver disorder. easy to be dehydrated. have hypertension, more than 180/110mmHg, or attending physician judged poor control of hypertension.

Design outcomes

Primary

Measure	Time frame
Change of sodium sensitivity of blood pressure	—

Countries

Japan

Contacts

Public ContactIchii Mitsuru

Osaka City General Hospital Department of nephrology and Hypertension

m41219791@yahoo.co.jp06-6929-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026